A Clinical observation was made on the patients with bladder tumor admitted to the Department of Urology, Kyung Hee University Hospital during the period from January, 1973 to December,1979 Followings were the results: 1. During the period, 57 cases of bladder tumor among the 1716 total number of in-patients were hospitalized, giving a incidence rate of 3.3%. 2. Age distribution was between 4 and 85 years, the highest incidence rate was in the age group of 60-69 years. 3. Hematuria was the most common symptom occurred in 87.7%, frequency in 61.1%. dysuria in 52.6% and the others. 4. Among the 53 cases performed I.V.P., 79.3% of cases revealed normal upper tract, filling defect in the bladder was observed in 69.8% of them. 5. Associated diseases with bladder tumor were B. P. H. or B. N. C. each in 12.3% and U. T. I. in 31. 6%. 6. Pathologic examination was possible on 49 cases, transitional cell carcinoma occupied 44 cases, in 89.8% and Grade I was found most frequently. 7. 14 cases were studied by the non-invasive, simple method as computerized tomography: the effective staging procedure in invasion of bladder wall itself could be diagnosed very helpfully but distant metastasis not diagnosed very exactly, comparison with the operation stage. 8. 47 cases were treated, T. U. R. or T. U. C. were tried initially in 21 cases.
Age Distribution ; Carcinoma, Transitional Cell ; Dysuria ; Hematuria ; Humans ; Incidence ; Neoplasm Metastasis ; Urinary Bladder Neoplasms* ; Urinary Bladder* ; Urology

The occurrence of an abdominal wall hematoma caused by abdominal paracentesis in patients with liver cirrhosis is rare. This paper presents a case of an abdominal wall hematoma caused by abdominal paracentesis in a 67-year-old woman with liver cirrhosis with a review of the relevant literature. Two days prior, the patient underwent abdominal paracentesis for symptom relief for refractory ascites at a local clinic. Upon admission, a physical examination revealed purpuric patches with swelling and mild tenderness in the left lower quadrant of the abdominal wall. Abdominal computed tomography revealed advanced liver cirrhosis with splenomegaly, tortuous dilatation of the para-umbilical vein, a large volume of ascites, and a large acute hematoma at the left lower quadrant of the abdominal wall. An external iliac artery angiogram showed the extravasation of contrast media from the left deep circumflex iliac artery. Embolization of the target arterial branches using N-butyl-2-cyanoacrylate was then performed, and the bleeding was stopped. The final diagnosis was an abdominal wall hematoma from the left deep circumflex iliac artery after abdominal paracentesis in a patient with liver cirrhosis.

Most T-cell lymphomas arise from mature alpabeta T-cells and commonly involve the nodes. Lymphomas bearing the gamadelta T-cell receptor (TCR) are very rare, and involve the lymph nodes minimally, if at all. Hepatosplenic gamadelta T-cell lymphoma is a recently identified, rare entity in which lymphoma cells bearing the gamadelta TCR infiltrate the sinusoids of the liver, splenic red pulp, and bone marrow. Its leukemic transformation is even more rare. Recently, we experienced a case of hepatosplenic gamadelta T-cell lymphoma in a 19-year-old woman who presented with epigastric pain, fever, massive splenomegaly, andpancytopenia. The splenectomy specimen and excisional biopsy of the liver revealed the infiltration of atypical T lymphocytes with the immunophenotypic markers of CD3 (+), CD45RO (pan-T antigen) (+), TIA-1(+), CD4(-),CD8 (-), CD56 (-), and S100 (-) in the sinusoids of the liver and splenic red pulp. Polymerase chain reaction (PCR) showed that these cells had the expression of the TCR gama gene rearrangements. Though the pancytopenia had improved after the splenectomy, the response of chemotherapy was transient. Her disease progressed rapidly and she expired in the leukemic phase. We report a case of hepatosplenic gamadelta T-cell lymphoma that developed in a young woman, along with a brief review of the literature.
Biopsy ; Bone Marrow ; Drug Therapy ; Female ; Fever ; Gene Rearrangement ; Glycogen Storage Disease Type VI ; Humans ; Liver ; Lymph Nodes ; Lymphoma ; Lymphoma, T-Cell* ; Pancytopenia ; Polymerase Chain Reaction ; Receptors, Antigen, T-Cell ; Splenectomy ; Splenomegaly ; T-Lymphocytes* ; Young Adult

Background: and Purpose The natural course of adult-onset moyamoya disease (MMD) is unknown, and there is no medical treatment that halts its progression. We hypothesized that progressive shrinkage of large intracranial arteries occurs in adult-onset MMD, and that cilostazol inhibits this process. Methods: Serial high-resolution magnetic resonance imaging (HR-MRI) was performed on 66 patients with MMD: 30 patients received cilostazol, 21 received other antiplatelets, and 15 received no antiplatelets or had poor compliance to them. Serial HR-MRI was performed (interval between MRI scans: 29.67±18.02 months, mean±SD), and changes in outer diameter, luminal stenosis, and vascular enhancement were measured. Factors affecting HR-MRI changes were evaluated, including vascular risk factors and the ring finger protein 213 gene variant. Results: The progression of stenosis to occlusion, recurrent ischemic stroke, and the development of new stenotic segments were observed in seven, seven, and three patients, respectively. Serial HR-MRI indicated that the degree of stenosis increased with negative remodeling (outer diameter shrinkage). Patients who received cilostazol presented significantly larger outer diameters and lower degrees of stenosis compared with other groups (p=0.005 and p=0.031, respectively). After adjusting for clinical and genetic factors, only cilostazol use was independently associated with negative remodeling (odds ratio=0.29, 95% confidence interval=0.10–0.84, p=0.023). While vascular enhancement was observed in most patients (61 patients), the progression of enhancement or the occurrence of new vascular enhancement was rarely observed on follow-up HR-MRI (6 and 1 patients, respectively). Conclusions Adult-onset MMD induces progressive shrinkage of large intracranial arteries, which cilostazol treatment may prevent. Further randomized clinical trials are warranted.